TERRANET
4.1.2020 13:22:09 CET | Business Wire | Press release
At next week’s International CES 2020, Terranet will demonstrate VoxelFlow - a 3D motion perception technology capable of detecting and classifying objects far more accurately and exponentially faster than Lidar. Terranet’s demo is timely considering Tesla CEO Elon Musk shocked the press just last April with his remarks: “Lidar is a fool’s errand. Anyone relying on Lidar is doomed. Doomed!” In a bold move, Swedish-headquartered Terranet plans on backing up Musk’s claims that Lidar is merely a dangerous shortcut to image recognition – a perilous reliance if that’s what the promised fully autonomous cars of the future will continue to use.
Invented by Dirk Smits, VoxelFlow was built upon the understanding that today’s camera-based computer vision and artificial intelligence navigation systems are simply too slow and subject to fundamental speed limits of perception using a frame based approach. Lidar has limited resolution and slow scanning rates, making it nearly impossible to distinguish between, for example, a fixed lamppost and a running child.
The underlying problem with Lidar or any existing camera/computer vision technology is that it cannot detect vulnerable road users with low latency. VoxelFlow on the other hand classifies dynamic moving objects at extremely low latency using very low computational power, producing 10 million 3D points per second, resulting in rapid edge detection without motion blur. The iPhone’s ‘selfie’ camera pales in comparison, producing a mere 33,000 light points per frame. Put into context, standard vehicles today and even those with autonomous driving roadmaps in place don’t use cameras much stronger than that of the iPhone’s selfie camera.
VoxelFlow’s capabilities are especially relevant considering harrowing statistics indicating that 80% of all crashes and 65% of all near-crashes involve driver inattention within the last 3 seconds of the crash. By providing life-saving decision making in milliseconds versus seconds, Terranet envisions transforming the pre-crash inattention that today accounts for roughly 1.35M road accident deaths into a forgotten collision-free swerve on the road.
“Terranet succeeding in proving VoxelFlow as a serious and necessary contender to Lidar is just the kind of shake-up the oft self-congratulatory autonomous driving community needs to kick start the new decade and save lives,” says Terranet CEO, Pär-Olof Johannesson.
To schedule a viewing of the VoxelFlow demo during CES, please contact Christina Björnström at +1-818-672-6954 or contact Lena Hägvall via email lena.hagvall@terranet.se
www.terranet.se
https://vimeo.com/377730923
ABOUT TERRANET
Terranet design radio and vision based ADAS software platforms for collision avoidance. Terranet is headquartered in Lund, Sweden, with offices in Stuttgart and California. Terranet Holding AB (publ) is listed on Nasdaq First North Premier.
Appointed Certified Adviser to Terranet Holding AB (publ) is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200103005392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom